Clementia Pharm (NASDAQ: CMTA) recently received a number of ratings updates from brokerages and research firms:

  • 8/31/2017 – Clementia Pharm is now covered by analysts at BTIG Research. They set a “buy” rating and a $32.00 price target on the stock.
  • 8/28/2017 – Clementia Pharm is now covered by analysts at Leerink Swann. They set an “outperform” rating and a $23.00 price target on the stock.
  • 8/28/2017 – Clementia Pharm is now covered by analysts at Wedbush. They set an “outperform” rating and a $26.00 price target on the stock.
  • 8/28/2017 – Clementia Pharm is now covered by analysts at Morgan Stanley. They set an “overweight” rating and a $27.00 price target on the stock.

Shares of Clementia Pharm (NASDAQ CMTA) traded down 1.72% on Thursday, reaching $16.01. The company’s stock had a trading volume of 152,887 shares. The firm’s 50 day moving average is $16.17 and its 200-day moving average is $15.53. The stock’s market cap is $488.74 million. Clementia Pharm has a 52-week low of $15.05 and a 52-week high of $18.95.

Clementia Pharmaceuticals Inc is a clinical stage biopharmaceutical company. The Company is engaged in developing disease-modifying treatments for patients suffering from debilitating bone and other diseases with high unmet medical need. Its lead product candidate, palovarotene, is an oral small molecule that binds and activates retinoic acid receptor gamma (an RARg agonist), and has activity in preventing abnormal new bone formation as well as scar tissue formation (or fibrosis) in a variety of tissues in animal models.

Receive News & Ratings for Clementia Pharm Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clementia Pharm and related companies with MarketBeat.com's FREE daily email newsletter.